The challenges for cancer chemoprevention

Abstract

The incidence of cancer is rising in parallel with an ageing populous thus increasing the strain on both treatment options and budgets for healthcare providers worldwide. New cancer therapies are being developed but at what cost? The new treatments are expensive and poor survival rates still exist for some cancers. What is needed now is to prevent or at least limit the disease occurring in the first place. This review evaluates the current situation and the progress in upcoming strategies as well as suggesting some areas for further research within the increasingly important field of cancer chemoprevention. The key principles of cancer chemoprevention are discussed and areas for improvement highlighted. Despite significant progress, chemoprevention has not been widely adopted. Cancer chemoprevention has many challenges to face but this only emphasises the size of the task. These hurdles include a lack of awareness of the benefits, a lack of interest and a lack of investment in taking prevention forward. Despite the huge potential importance of cancer prevention and clinical success stories such as the well-publicised HPV vaccine, the challenges remain significant. With cancer and its treatment being a global issue, the opportunities offered by chemoprevention must be re-evaluated and uptake of chemoprevention actively encouraged. If chemoprevention is to be adopted successfully, a holistic approach is required. This approach will involve multidisciplinary teams of healthcare providers and scientists with the big challenge particularly for medicinal chemists being to design and synthesise the ideal chemopreventative agent.

One Pot Synthesis and Biological Evaluation of Some New Pyridine‐3,5‐dicarbonitrile Derivatives

“…From the combined results, we conclude that 1 q and 1 r are the most active among all compounds in the dormant stage of tuberculosis and they have shown almost 70–97% inhibition, while in the active stage 1 s is only found to be active. As chemoprevention is the growing demand for most of the disease, the activity of 1 q, 1 r and 1 s showed promising results against dormant stage which could be the lead in the development of antitubercular drugs. From the results, compounds with aromatic ring substituted with electron donating groups have shown excellent activity (MIC 62.5 μg/mL) against selected bacterial pathogens while the compounds with aromatic substitution with electron withdrawing groups have shown very potent activity against selected fungal pathogens.…”

Prospect of natural products in glioma: A novel avenue in glioma management

“…Despite significant advancement in cancer treatment, there are still some limitations in cancer chemotherapy including the high cost of treatment (Penny & Wallace, ), multidrug resistance (Chi et al, ), and cytotoxicity to healthy tissue (Hersberger, Boeni, & Arnet, ). Moreover, most of the chemotherapeutic drugs aim to inhibit cell proliferation, whereas invasion and metastasis inhibition is also necessary (Penny & Wallace, ). Natural compounds are tried as a single agent or combination therapy to overcome these limitations.…”

Recent Advances and Developments of in vitro Evaluation of Heterocyclic Moieties on Cancer Cell Lines

“…The numbers of new cases are expected to rise by about 70 % over the next decades. By 2030, the world‐wide burden is expected to grow to 21.7 million new cancer cases . The future burden will probably be even larger because of the adoption of western lifestyles, such as smoking, physical inactivity, poor diet and fewer childbirths, in economically developing countries.…”